EUVIMEDEUVIMED entdecken
Metaanalyse

Meta-analysis of the clinical efficacy and safety of T-DM1 in the treatment of HER2-positive breast cancer

Furong Liu, Yuehua Li, Dinghua Yang, Li Tang, Qian Yang, Majiao Jiang, Leilei Tian, Jingjing An

Indian Journal of Cancer · 2024-01 · 61 (1) · 146-155

DOI: 10.4103/ijc.ijc_223_24 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Indian Journal of Cancer, online erschienen am 02.05.2024. Verfasst von Furong Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Operating Room, West China School of Nursing, Sichuan University, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Ado-Trastuzumab Emtansine, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This meta-analysis aims to comprehensively evaluate the efficacy and safety of T-DM1 in treating HER2-positive breast cancer, providing insights for clinical practice. We conducted a literature search in PubMed, Cochrane Library, and Embase databases up to September 2023, collecting randomized controlled trials and cohort studies on T-DM1 for HER2-positive breast cancer. Out of 316 initially retrieved articles, 12 studies meeting the quality and inclusion criteria were included after a rigorous screening process. We used RevMan 5.3 software for the meta-analysis, employing fixed or random-effect models. Odds ratios (RRs) and 95% confidence intervals (CIs) were calculated as effect size measures. We conducted sensitivity analyses and assessed publication bias to ensure the results’ stability and reliability. In seven studies, T-DM1 treatment significantly prolonged OS in patients with HER2-positive breast cancer [hazard ratio (HR) = 0.70, 95% CI: 0.64–0.77, P < 0.01], and the effect was especially pronounced in patients with advanced disease (HR = 0.64, 95% CI: 0.54–0.76, P < 0.001). Analysis of pCR rates did not show a significant difference (OR = 0.91, 95% CI: 0.48–1.73, P = 0.77). In five studies, ORR improved, but the difference between the two groups was not significant (OR = 1.16, 95% CI: 0.66–2.05, P = 0.61). Analysis of progression-free survival (PFS) showed a significant improvement in the experimental group relative to the control group (HR = 0.69, 95% CI: 0.57–0.84, P = 0.0003). Regarding the incidence of total adverse events, no significant difference was seen between the two groups (OR = 2.16, 95% CI: 0.98–4.79, P = 0.06), but for specific adverse events, such as leukopenia and neutropenia, the T-DM1 group demonstrated a significant reduction relative to the other treatment regimens. The results underscore the potential of T-DM1 in enhancing survival among patients with advanced HER2-positive breast cancer, yet they also highlight variability in effectiveness concerning pCR rate and ORR. The findings on adverse effects underscore the necessity of a balanced consideration of T-DM1’s risks and benefits. Future research should focus on a more detailed examination of responses in varied patient populations, long-term outcomes, and a thorough economic evaluation of T-DM1, along with an exploration into treatment resistance. This will provide a more nuanced understanding of T-DM1’s role in the treatment landscape of HER2-positive breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAdo-Trastuzumab EmtansineErb-b2 Receptor Tyrosine KinasesHumansFemaleAntineoplastic Agents, Immunological

Substanzen

Ado-Trastuzumab EmtansineErb-b2 Receptor Tyrosine KinasesAntineoplastic Agents, ImmunologicalERBB2 protein, human

Autor:innen und Institutionen

  • Department of Operating Room, West China School of Nursing, Sichuan University, West China Hospital, Sichuan University, Chengdu, China.

Zitieren

APA

Liu, F., Li, Y., Yang, D., Tang, L., Yang, Q., Jiang, M., Tian, L., & An, J. (2024). Meta-analysis of the clinical efficacy and safety of T-DM1 in the treatment of HER2-positive breast cancer. Indian Journal of Cancer, 61(1), 146-155. https://doi.org/10.4103/ijc.ijc_223_24

Vancouver

Liu F, Li Y, Yang D, Tang L, Yang Q, Jiang M, et al. Meta-analysis of the clinical efficacy and safety of T-DM1 in the treatment of HER2-positive breast cancer. Indian Journal of Cancer. 2024;61(1):146-155. doi:10.4103/ijc.ijc_223_24

BibTeX
@article{Liu2024,
  author = {Liu, Furong and Li, Yuehua and Yang, Dinghua and Tang, Li and Yang, Qian and Jiang, Majiao and Tian, Leilei and An, Jingjing},
  title = {Meta-analysis of the clinical efficacy and safety of T-DM1 in the treatment of HER2-positive breast cancer},
  journal = {Indian Journal of Cancer},
  year = {2024},
  volume = {61},
  number = {1},
  pages = {146--155},
  doi = {10.4103/ijc.ijc_223_24}
}
Kostenlos starten →